HBT Financial vs QCR
HBT and QCRH side by side, both in commercial banks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HBT and QCRH compare
QCR is the larger company, worth 1.2 times as much as HBT Financial ($1.6B against $1.3B).
On earnings, QCR is cheaper: it trades at 11.9× trailing earnings, against 15.6× for HBT Financial.
HBT Financial grew revenue faster over the last twelve months (15.6% versus −2.3% for QCR).
QCR keeps more of each dollar of sales as profit, with a net margin of 35.8% compared with 29.0% at HBT Financial.
Both pay dividends: HBT Financial yields 2.6% and QCR 0.41%.
QCR scores higher on the StockData Score (13 against 11 for HBT Financial), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HBT | QCRH |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $1.6B |
| Share price | $36.25 | $100.56 |
| Change, 1 year | 52.1% | 28.3% |
| Change, 5 years | 99.2% | 82.2% |
| Beta (5Y) | 0.20 | 0.51 |
| Employees | 826 | 967 |
| StockData Score | ||
| Total score | 11 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 3 | 5 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 2 | 2 |
| Valuation | ||
| P/E | 15.6× | 11.9× (better) |
| P/S | 4.9× | 4.2× (better) |
| P/B | 1.7× | 1.4× (better) |
| P/FCF | – | 2.1× |
| PEG | 2.01 | 1.40 (better) |
| FCF yield | – | 48.1% |
| Fair value | $26.87 | $89.95 |
| Margin of safety | −34.9% | −11.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 15.6% (better) | −2.3% |
| Revenue growth, 5Y average | 9.3% (better) | 3.4% |
| Net income growth (TTM) | 1.3% | 25.9% (better) |
| EPS growth (TTM) | −3.7% | 27.2% (better) |
| EPS growth, 5Y average | 12.7% | 14.5% (better) |
| Profitability | ||
| Net margin | 29.0% | 35.8% (better) |
| FCF margin | – | 200% |
| Return on equity | 11.6% | 12.9% (better) |
| Financial health | ||
| Debt / equity | – | 0.01 |
| Altman Z-score | 0.25 | 0.28 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.6% (better) | 0.41% |
| Payout ratio | 37.3% | – |
| Years of dividend growth | 4 (better) | 0 |
| Dividend growth, 5Y average | 7.0% (better) | 0.00% |
| Buyback yield | 1.3% (better) | −0.16% |
| Shareholder yield | 4.0% (better) | 0.25% |
| Ownership | ||
| Held by institutions | 25.7% | 77.6% |
| Held by insiders | 52.8% | 3.1% |
| Insider net buying, 12 months | −$1.0M | −$903K (better) |
| Short interest, % of float | 6.7% | 3.0% |
Go deeper
- HBT stock overview
- HBT income statement
- HBT valuation and score
- QCRH stock overview
- QCRH income statement
- QCRH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.